Additional chromosomal abnormalities (ACA) are rather common in Ph+ acute lymphoblastic leukemia (ALL). However, their prognostic significance in the era of protein tyrosine kinase inhibitors and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still poorly known. A recent study [1] has shown that ACA exert unfavorable effect upon HSCT results in adult patients with Ph+ALL.
Introduction Ph 1 -positive acute lymphoblastic leukemia (Ph+ALL) ranks a special place among lymphoid tumors. Initially, Ph 1 positivity in ALL cells seemed an unexpected finding, since it challenged a specificity of t(9;22) translocation for chronic myeloid leukemia [17] . Afterwards, upon data gaining, it has become clear that Ph+ ALL may occur in all age groups, being more common in aged people, with minimal rates shown for children. Its prevalence is as high as 20% among adult ALL patients [15] . Until more recent times, the Ph+ ALL was considered an extremely unfavorable clinical variant with respect to all known treatment modes including hematopoietic stem cell transplantation (HSCT) [15] . This problem was solved as soon as different tyrosine kinase inhibitor drugs (TKIs) were introduced to clinics, thus enabling stable molecular remissions of the disease [3, 6, 13, 18] , and their usage for successful HSCT [2, 16, 23] including autologous (auto-) HSCTs [4, 7, 8, 25] . ACA in Ph+ ALL are commonly seen, being described for 30-60% of the cases [5, 11, 14, 24] . Evaluation of allo-HSCT outcomes has shown that their prognosis depends on presence or absence of additional chromosome aberrations in cases of Ph 1 chromosome positivity [1] . Moreover, it should be kept in mind that the ACA in Ph+ ALL patients could not be definitive. In particular, efficiency of chemotherapy and HSCT may be very good in cases of Ph 1 chromosome combined with high hyperdiploidy [22] . We have previously confirmed it in our studies [9] . Such clinical aspect seems to be of high importance, in view of revisiting auto-HSCT for Ph+ ALL treatment [7, 8, 25] .
Our study concerned a retrospective analysis of allo-HSCT performed in a mixed cohort of children and adults with Ph+ ALL who exhibited different clinical, transplant and cytogenetic characteristics.
Patients and Methods
The study was performed in a group of sixty-five patients with Ph+ ALL who underwent allo-HSCT at the First St. Petersburg I. Pavlov State Medical University over 2008 to 2015. We have used short-term 24-hour culturing of bone marrow cells without mitogen stimulation. Cytogenetic studies were carried out with a GTG chromosome staining using a standard technique [9] . Fluorescent in situ hybridization (FISH) with specific DNA probes proceeded according to the manufacturers' protocols (MetaSystems, Germany; CytoCell, Great Britain). Interpretation of chromosomal aberrations was performed in accordance with an International System for Human Cytogenetic Nomenclature [20] .
Evaluation of overall survival (OS) and event-free survival (EFS) was carried out in the patients with different demographic and clinical characteristics including gender and age, donor type, clinical state at the HSCT, conditioning regimen, source of stem cells and number of stem cells transplanted.
The overall survival (OS) has been determined as the time period passed since HSCT to the patient's death (for any reasons), or until the last examination date. Event-free survival (EFS) was evaluated as a time from HSCT to any adverse event (non-achievement of remission post-transplant, relapse, or death for any reasons), or till the last examination date.
Statistical evaluation was performed with digital package 'R' , version 3.1. 
Results
The group of patients included 26 females (40%), and 39 males (60%), at the age between 5 and 48 years (a median of 26 years). Table 1 represents clinical and transplantation characteristics of the cohort under study. Thirty-one patients (48%) received allo-HSCT in the 1 st remission, 20 subjects (31%) were transplanted in the 2 nd remission, whereas 14 (21%) of the patients underwent allo-HSCT in active stage of the disorder. Bone marrow was a source of stem cells in 31 patients (48%), whereas peripheral blood stem cell transplants were used in 32 subjects (49%). Two patients got stem cells from the both sources. Reduced-intensity conditioning regimens (RIC) were used in 36 cases (55%), myeloablative treatment, in 29 cases (45%). Eighteen patients (28%) had HLA-identical sibling in their families; whereas 42 patients (65%) could be transplanted from HLA-matched unrelated donors found in an international registry. In 5 cases (7%), a related haploidentical HSCT was performed, since HLAmatched donor was absent in the family or blood donor Registries.
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Cytogenetic characteristics of Ph-positive ALL Primary diagnosis of Ph+ ALL was established by a standard cytogenetic examination performed in 53 (80%) of the patients. In 12 subjects (18%), the diagnosis was based on a fusion chimeric BCR-ABL gene found by FISH technique and chimeric bcr/abl transcript (р190 and/or p210) revealed with PCR.
Afterwards, we considered karyotypic changes in 53 patients with described pre-transplant cytogenetics. A t(9;22) (q34;q11) translocation, as sole karyotypic aberration, has been revealed in 33 patients, including 9 children (38%) and 24 (62%) adults. Accessory chromosomal anomalies were found in 20 patients, 5 (33%), in children and 15 (67%) in adults. The cytogenetic data for the 20 patients with additional chromosomal aberrations (ACA) are represented in Table 2 . Both quantitative and structural ACA have been detected. Numerical abnormalities beared, mainly, on the chromosomes 1, 7, 8, 9, 10, being found in 12 out of 20 cases (60%). Trisomy 1 was nonrandom, being found in 2 patients (№5, 6). Similar repeated findings were made for trisomy10 (№4, 20), trisomy 22 (№4, 16), monosomy 7 (№8, 12). Trisomy 2 (in №20), trisomy 17 and 19 (№2), monosomy 9 (№16) were revealed in single patients. A univariate analysis (Table 3) has shown significant differences in OS and EFS after allo-HSCT for the patients differing in their clinical stage at transplantation (for EFS only), donor type, as well as for groups with ACA, complex chromosomal aberrations (≥3 per karyotype), or ACA-free.
Our data suggest that clinical efficiency was higher for transplantations performed at the 1 st remission (for EFS only), in cases of matched related and unrelated donors, in absence of ACA in karyotype (for OS only), and, in particular, for complex chromosome aberrations (for OS only) (Fig. 3, 4) .
Meanwhile, no significant differences were obtained in the patients differing for their age, gender, conditioning regimens, stem cell source, time period from initial diagnosis to HSCT, and amount of transplanted CD34+ cells. The results of multivariate analysis ( Table 4 ) have shown that a presence of ≥3 chromosomal abnormalities in karyotype is an independent predictor for OS in ALL patients with t(9;22)/BCR-ABL translocation. Meanwhile, clinical stage at the time of allo-HSCT seems to be an independent predictor of event-free survival (EFS) of these patients. CliniCal artiCles
Discussion
Our study has confirmed recent conclusions on predictive significance of ACA in Ph+ALL patients [1] . According to several studies [5, 24] , ACA in Ph+ ALL took place in 30-60% of these patients, and some of them underwent HSCT. As a rule, ACA affect chromosome pairs 7 to 9, 21 and 22 [11, 24] . Since advent of tyrosine kinase inhibitors (TKIs), predictive significance shifted towards ACA of chromosomes 9 and 22, making questionable a predictive role of other chromosomes.
[21]. In our cohort, the structural changes in chromosomes 9 and 22 with 9p deletion and accessory Ph'-chromosome encountered in 6 patients. Moreover, ACA included also structural changes of chromosomes 5 (n=4), 7 (n=3), 1 (n=3), 17 (n=2) and some others. When discussing a role of ACA in Ph+ ALL patients, one should mention that some of them, by contrary, might lengthen OS and EFS. In particular, such situation is typical to the patients with a combination of one or two Ph 1 -cromosomes with high hyperdiploid karyotype [5, 19, 22] . In most of them, it was rather easy to achieve complete remission, due to positive predictive effect of high hyperdiploidy. Such patients were absent from our cohort. In the past, however, we have observed several ALL patients with two Ph' chromosomes and high hyperdiploid karyotype who developed complete remission, even at standard chemotherapy, without TKI's, with subsequent consolidation by means of autologous HSCT [9] . Some workers presume that only a combination of glucocorticoids and TKI's is today sufficient to achieve a molecular remission, which could be fixed with auto-transplant [4, 7, 8] . As seen from our results, this cohort is heterogeneous, with respect to cytogenetic and prognostic parameters. Hence, appropriate therapy should be differentiated and based on cytogenetic data. In case of "favorable" combination of Ph' chromosome and high hyperdiploid karyotype, the patients should be initially prepared by glucocorticoids and TKI's (without application of), then followed by auto-HSCT. What concerns more toxic protocols of therapy followed by auto-HSCT, they should be used, first of all, for treating the patients with other ACA types. Moreover, chemotherapy causes both de novo chromosome damage in Ph+ cells, and triggers a complex, prognostically adverse process of clonal evolution [10] . A resulting delay with HSCT in adult patients with Ph+ALL also remains unacceptable.
Conclusion
Our data show broad cytogenetic heterogeneity among leukemia patients with Ph+ ALL before HSCT. A significant subgroup exhibits additional chromosomal abnormalities which are associated with inferior clinical outcomes post-transplant. This phenomenon can be due to clonal evolution of malignant karyotype, or chemotherapy performed before HSCT, thus requiring further studies in the field.
